Press "Enter" to skip to content

Regeneron Starts COVID-19 Antibody Cocktail Late-Stage Trial, Shares Rise

Regeneron Pharmaceuticals Inc mentioned on Monday it started late-stage medical trials to evaluate the effectiveness of its antibody cocktail in stopping and treating COVID-19, sending its shares up practically 4%.

The trial, run collectively with the National Institute of Allergy and Infectious Diseases (NIAID), would check REGN-COV2’s capacity to stop an infection in those that have had shut publicity to a COVID-19 affected person.

REGN-COV2, an experimental remedy, has additionally entered into mid-to-late stage section of two trials testing its effectiveness in hospitalized and non-hospitalized COVID-19 sufferers, Regeneron mentioned.

Regeneron is among the many few front-runners who’ve begun human trials testing their experimental therapies to combat COVID-19, together with Gilead Sciences, Eli Lilly and AbbVie.

Regeneron in June started human trial of the antibody cocktail as a remedy for COVID-19, with an “adaptive” design to shortly transfer to incorporate hundreds of sufferers.

The late-stage trial can be performed throughout 100 websites and anticipated to enroll 2,000 sufferers within the U.S. It follows a security evaluation of the cocktail in an early-stage trial by an impartial committee.

Antibodies are proteins made by the physique’s immune system that acknowledge, bind and neutralize an invading virus.

Regeneron’s cocktail – a mixture of an antibody made by the corporate and a second antibody remoted from recovered COVID-19 sufferers – is designed to bind the antibodies to the coronavirus’ spike protein.

The drugmaker was additionally testing its rheumatoid arthritis drug, Kevzara, with Sanofi to deal with COVID-19, which on Thursday failed to fulfill the principle purpose of a U.S. examine testing it in essentially the most critically sick COVID-19 sufferers.

Shares of the drugmaker had been up 3.6% at $645 in buying and selling earlier than the bell.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *